Steven K. Libutti

The Cancer Institute of New Jersey operates as a cancer centre. The firm offers cancer care for adults and children, providing access to the medicines and treatment options. It also offers clinical, patient education resources and support services. The company was founded in and is headquartered in New Brunswick, NJ.

Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is the only National Cancer Institute-designated comprehensive cancer center in New Jersey. Rutgers Cancer Institute has locations in New Brunswick and at University Hospital in Newark, as well as through RWJBarnabas Health facilities. The institute offers advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy, and complex surgical procedures. Patients have access to cutting-edge therapies such as precision medicine and immunotherapy, many of which are not widely available. The top cancer researchers and clinicians throughout the state collaborate to apply the latest technologies, therapies, and approaches to improve cancer diagnosis and treatment.

PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin.